SI21351A - Zdravljenje odvisnosti od psihostimulansov - Google Patents

Zdravljenje odvisnosti od psihostimulansov Download PDF

Info

Publication number
SI21351A
SI21351A SI200200305A SI200200305A SI21351A SI 21351 A SI21351 A SI 21351A SI 200200305 A SI200200305 A SI 200200305A SI 200200305 A SI200200305 A SI 200200305A SI 21351 A SI21351 A SI 21351A
Authority
SI
Slovenia
Prior art keywords
cocaine
methyl
pharmaceutically acceptable
acid addition
didehydro
Prior art date
Application number
SI200200305A
Other languages
English (en)
Slovenian (sl)
Inventor
Igor Krisch
Marko �Ivin
Nata�A Milivojevi�
Rudolf Ru�man
Breda Bole
Uro� Urleb
Original Assignee
LEK farmacevtska dru�ba d.d.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by LEK farmacevtska dru�ba d.d. filed Critical LEK farmacevtska dru�ba d.d.
Priority to SI200200305A priority Critical patent/SI21351A/sl
Priority to US10/539,501 priority patent/US7632843B2/en
Priority to SI200331548T priority patent/SI1581219T1/sl
Priority to PCT/SI2003/000045 priority patent/WO2004054578A1/en
Priority to AU2003288888A priority patent/AU2003288888A1/en
Priority to DE60325642T priority patent/DE60325642D1/de
Priority to EP03781272A priority patent/EP1581219B1/de
Priority to AT03781272T priority patent/ATE418985T1/de
Publication of SI21351A publication Critical patent/SI21351A/sl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/48—Ergoline derivatives, e.g. lysergic acid, ergotamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SI200200305A 2002-12-17 2002-12-17 Zdravljenje odvisnosti od psihostimulansov SI21351A (sl)

Priority Applications (8)

Application Number Priority Date Filing Date Title
SI200200305A SI21351A (sl) 2002-12-17 2002-12-17 Zdravljenje odvisnosti od psihostimulansov
US10/539,501 US7632843B2 (en) 2002-12-17 2003-12-11 Treatment of psychostimulant addiction
SI200331548T SI1581219T1 (sl) 2002-12-17 2003-12-11 Zdravljenje odvisnosti od psihostimulansov
PCT/SI2003/000045 WO2004054578A1 (en) 2002-12-17 2003-12-11 Treatment of psychostimulant addiction
AU2003288888A AU2003288888A1 (en) 2002-12-17 2003-12-11 Treatment of psychostimulant addiction
DE60325642T DE60325642D1 (de) 2002-12-17 2003-12-11 Behandlung von psychostimulant-sucht
EP03781272A EP1581219B1 (de) 2002-12-17 2003-12-11 Behandlung von psychostimulant-sucht
AT03781272T ATE418985T1 (de) 2002-12-17 2003-12-11 Behandlung von psychostimulant-sucht

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SI200200305A SI21351A (sl) 2002-12-17 2002-12-17 Zdravljenje odvisnosti od psihostimulansov

Publications (1)

Publication Number Publication Date
SI21351A true SI21351A (sl) 2004-06-30

Family

ID=32590099

Family Applications (2)

Application Number Title Priority Date Filing Date
SI200200305A SI21351A (sl) 2002-12-17 2002-12-17 Zdravljenje odvisnosti od psihostimulansov
SI200331548T SI1581219T1 (sl) 2002-12-17 2003-12-11 Zdravljenje odvisnosti od psihostimulansov

Family Applications After (1)

Application Number Title Priority Date Filing Date
SI200331548T SI1581219T1 (sl) 2002-12-17 2003-12-11 Zdravljenje odvisnosti od psihostimulansov

Country Status (7)

Country Link
US (1) US7632843B2 (de)
EP (1) EP1581219B1 (de)
AT (1) ATE418985T1 (de)
AU (1) AU2003288888A1 (de)
DE (1) DE60325642D1 (de)
SI (2) SI21351A (de)
WO (1) WO2004054578A1 (de)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4935429A (en) * 1985-10-25 1990-06-19 Dackis Charles A Method of treating psychostimulant addiction
US5480885A (en) * 1991-07-01 1996-01-02 Lek, Tovarna Farmacevtskih In Kemicnih Ergoline derivatives of 1-propinylamine, a process for the manufacture thereof and the use thereof for medicaments
US5441961A (en) * 1992-08-27 1995-08-15 Eli Lilly And Company Substituted cyclo or bicycloalkylamides of (8β)-6-(substituted) ergolines
TW252979B (de) * 1992-12-24 1995-08-01 Erba Carlo Spa
WO2001041763A1 (en) * 1999-12-10 2001-06-14 University Of Cincinnati Treatment of addiction disorders

Also Published As

Publication number Publication date
WO2004054578A1 (en) 2004-07-01
US20060014775A1 (en) 2006-01-19
DE60325642D1 (de) 2009-02-12
AU2003288888A1 (en) 2004-07-09
ATE418985T1 (de) 2009-01-15
EP1581219A1 (de) 2005-10-05
EP1581219B1 (de) 2008-12-31
US7632843B2 (en) 2009-12-15
SI1581219T1 (sl) 2009-06-30

Similar Documents

Publication Publication Date Title
Mello et al. Buprenorphine suppresses cocaine self-administration by rhesus monkeys
Schenk et al. Cocaine-seeking produced by experimenter-administered drug injections: dose-effect relationships in rats
Comer et al. Effects of buprenorphine and naltrexone on reinstatement of cocaine-reinforced responding in rats.
SK344992A3 (en) Use of diphenylbutylpiperazinecarboxamide in the tretament of disorders following from abusing of different matters
Martellotta et al. Isradipine inhibits nicotine intravenous self-administration in drug-naive mice
CA2893238C (en) D-methadone for the treatment of psychiatric symptoms
Corrigall et al. Nicotine self-administration and locomotor activity are not modified by the 5-HT3 antagonists ICS 205–930 and MDL 72222
Miller et al. A hypothesis for a common neurochemical basis for alcohol and drug disorders
Rasmussen et al. The selective mGlu2/3 receptor antagonist LY341495 exacerbates behavioral signs of morphine withdrawal and morphine-withdrawal-induced activation of locus coeruleus neurons
Spealman et al. Differential modulation of behavioral effects of cocaine by low-and high-efficacy D1 agonists
Budzynska et al. Effects of calcium channel antagonists on the motivational effects of nicotine and morphine in conditioned place aversion paradigm
Homberg et al. Individual differences in the effects of serotonergic anxiolytic drugs on the motivation to self-administer cocaine
Villégier et al. Serotonergic mechanism underlying tranylcypromine enhancement of nicotine self‐administration
Haile et al. Cocaine self-administration and locomotor activity are altered in Lewis and F344 inbred rats by RTI 336, a 3-phenyltropane analog that binds to the dopamine transporter
George et al. A psychopharmacology of motivation and reward related to substance abuse treatment.
SI21351A (sl) Zdravljenje odvisnosti od psihostimulansov
Gorelick Pharmacological treatment
Glick et al. Effects of cyclazocine on cocaine self-administration in rats
Antkiewicz-Michaluk et al. An endogenous neuroprotectant substance, 1-methyl-1, 2, 3, 4-tetrahydroisoquinoline (1MeTIQ), prevents the behavioral and neurochemical effects of cocaine reinstatement in drug-dependent rats
Palmatier et al. Examination of GABAergic and dopaminergic compounds in the acquisition of nicotine-conditioned hyperactivity in rats
Sershen et al. Characterization of multiple sites of action of ibogaine
Ellinwood Neuropharmacology of amphetamines and related stimulants
WO1997041858A1 (en) Pyridyl- and pyrimidyl-piperazines in the treatment of substance abuse disorders
Ferrari et al. B-HT 920 stimulates feeding and antagonizes anorexia induced by ACTH and immobilisation
KR100736016B1 (ko) 알코올 및/또는 담배 소비 감소를 위한 의약 및 방법

Legal Events

Date Code Title Description
IF Valid on the event date
KO00 Lapse of patent

Effective date: 20110811